Evidence map›Paper›PMID 30588036›Full record

ArticleOncoTargets and therapy2019

Qianfeng Zhuang, Zhen Chen, Jie Shen, Min Fan, Dong Xue, Hao Lu, Renfang Xu, Xiaozhou He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Qianfeng ZhuangDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Zhen ChenDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Jie ShenDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Min FanDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Dong XueDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Hao LuDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Renfang XuDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Xiaozhou HeDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China, czyyhxz@163.com.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis meta-analysis evaluated the clinicopathologic and prognostic significance of MATERIALS AND

methodsThe ORs or HRs and their 95% CIs were calculated. Trial sequential analysis was conducted.

resultsTwenty-two articles that included 1,421 patients with RCC and 724 controls were identified.

conclusion

Indexed as

clinical featuresmethylationRAS association domain family protein 1Asurvival

Identifiers

PMID30588036
PMCPMC6304251
OpenAlexW2904667620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.